

Development of new method and protocol for cryopreservation related to embryo and oocytes freezing in terms of fertilization rate: A comparative study including review of literature

Mayadhar Barik, Minu Bajpai, Santosh Patnaik¹, Pravash Mishra², Priyamadhava Behera³, Sada Nanda Dwivedi⁴

Departments of Pediatric Surgery, ¹Ocular Pharmacology and Pharmacy, ³Centre for Community Medicine and ⁴Biostatistics, AllIMS, New Delhi, ²Department of Anatomy, AllIMS, Bhubaneswar, Odisha, India

Abstract

Background: Cryopreservation is basically related to meritorious thin samples or small clumps of cells that are cooled quickly without loss. Our main objective is to establish and formulate an innovative method and protocol development for cryopreservation as a gold standard for clinical uses in laboratory practice and treatment. The knowledge regarding usefulness of cryopreservation in clinical practice is essential to carry forward the clinical practice and research.

Materials and Methods: We are trying to compare different methods of cryopreservation (in two dozen of cells) at the same time we compare the embryo and oocyte freezing interms of fertilization rate according to the International standard protocol.

Results: The combination of cryoprotectants and regimes of rapid cooling and rinsing during warming often allows successful cryopreservation of biological materials, particularly cell suspensions or thin tissue samples. Examples include semen, blood, tissue samples like tumors, histological cross-sections, human eggs and human embryos. Although presently many studies have reported that the children born from frozen embryos or “frosties,” show consistently positive results with no increase in birth defects or development abnormalities is quite good enough and similar to our study (50–85%).

Conclusions: We ensure that cryopreservation technology provided useful cell survivability, tissue and organ preservation in a proper way. Although it varies according to different laboratory conditions, it is certainly beneficial for patient’s treatment and research. Further studies are needed for standardization and development of new protocol.

Key Words: Autologous bone marrow, cryopreservation, human oocytes, stem cells, transplant, unfertilized oocytes

Address for correspondence:

Dr. Mayadhar Barik, Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi - 110 029, India. E-mail: mayadharbarik@gmail.com

Received: 29.07.2013, Accepted: 09.11.2015

Access this article online	
Quick Response Code:	Website: www.advbiores.net
	DOI: 10.4103/2277-9175.185576

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Barik M, Bajpai M, Patnaik S, Mishra P, Behera P, Dwivedi SN. Development of new method and protocol for cryopreservation related to embryo and oocytes freezing in terms of fertilization rate: A comparative study including review of literature. *Adv Biomed Res* 2016;5:117.

INTRODUCTION

Cryopreservation is a process of reserving whole body tissues and cells by cooling to sub-zero temperatures (77K or -196°C boiling point of liquid nitrogen). Biological activity, biochemical reactions lead to cell death. Cryopreservation solutions required to preserve and tissue process. However, few of the times low temperature destroys tissues of liver, heart and other body organs. Therefore storage and transplantations samples should be kept carefully. Here we documented the usefulness of cryopreservation in routine practice for patients and future management.

MATERIALS AND METHODS

Study design: We performed

A hospital laboratory-based comparative study.

Study duration

Up-to-date information provided since (2000–2016).

Related samples information given unlike

Humanocyte, ovarian tissue, fresh embryos, frequent infrozenembryotransfer (FRET) cycles, endometrium preparation, embryo, blastocysts, fresh pre-embryos, hematopoietic stem cells (HSCs), umbilicalcordblood (UCB), human spermatozoa, *in vitro* fertilization (IVF), intracytoplasmic sperm injection (ICSI), semen, gamete, follicle, autologous transplantation, human lymphocytes, gonadotrophin releasing hormone analogue (GnRHa), ZPNoocytes, hepatocytes, fluid from the intravascular compartment, bone marrows, and mature blood cells (MBCs).

Sample preservation

We reviewed through medical literature and summarized recent advances in protocol development and its usefulness.

Statistical analysis

We have used simple statistics available in excel and SPSS software ver. 17.

RESULTS

Basically cryopreservatives were used for freezing and measure the viability. Although the frozen unit allowed 72 hr, it should be verified as per constructive maintenance of temperature. Accordingly thawing procedure and donor unit look forward for optimized temperature of cryopreservation. Although different conditions attributed with tissue specific, we should not ignore liquid nitrogen. CCIF3 (Chloro trifluoro methane) is more useful for tissue processing.^[1] The ideal conditions -500 mg of tissue be immersed for

approximately 7-10 s.^[2] Presently we observe liquid nitrogen slushing within a container. Therefore cryogenic storage vials are required for suction. The partial vacuum in the container above the liquid helps to preserve tissues. The samples are dropped into slowly and stored in the container [Table 1].^[2,3]

Human oocyte cryopreservation is a novel technology in which a woman's eggs are extracted, frozen, and stored. Later, whenever she is ready for pregnancy, the eggs can be thawed, fertilized, and transferred to the uterus as embryos.^[4] Bernardo and Fuller recognized that cryopreservation of unfertilized humanocytes would make a significant contribution to the treatment of infertility. Successful pregnancies have resulted from cryopreserved oocytes. Studies on the effects of cooling, membrane permeability, cryoprotectant addition and ice formation have been performed on human oocytes by a number of groups. We are trying to improve this technique and developed new concept.^[1] A higher fertilization rate (75%) could be achieved after thawing, using 1,2 propanediolas as cryoprotectant. Polyploidy rates of 20% and 40% were observed using dimethyl sulfoxide (DMSO) and 1,2propanediol as cryoprotectants, respectively. Using the ultra-cooling method the survival rate was poor (4%).^[5] The paucity of well-controlled studies currently precludes valid comparisons between legal approaches. Legal restrictions on the ability to select embryos from cryopreserved oocytes in countries such as Italy also obscure attempts to assess oocyte cryopreservation objectively.^[6] Oocyte cryopreservation is aimed at three particular groups of women: (1) Women diagnosed with cancer who have not yet begun chemotherapy or radiotherapy. (2) Women who are undergoing treatment with assisted reproductive technologies (ARTs) would like to preserve the ir future option to have children either because they donot yet have a partner, or for other personal reasons.^[7] (3) Women with a family history of early menopause may go for fertility preservation. With egg freezings they will have a frozen store of eggs, in the likelihood that their eggs are depleted at an early age. The person has the option of using a few eggs for fertilization, and preserving the rest of the unfertilized eggs for future use.^[8]

Recent studies focused that the rate of birth defects and chromosomal defects in cryopreserved oocyte are comparable with that of natural conception. The potential advantages associated with the ability of freeze and store human oocytes successfully have been well established. Another way there is a possibility of women, with no medical indications and no immediate plans to conceive, being able to store "young eggs" for potential use at a later date.^[9]

Table 1: Newly developed method and protocol designed for cryopreservation technology as gold standard including treatment and long term follow up

OR	DM	CPT	CPV	CT	OR	ST	FT	SV	SF	SR + RM
Human oocyte	Egg Freezing (Transvaginal oocyte retrieval)	CPT which replaces most of the water in the cell	Vitrification	Slow cooling	Metaphase-II	Quickly	SlowFrozen	Improved	Asistedre productive Technology	40 to 50%
Ovarian tissue	Standard Freezing method	Glycerol	Fertility preservatio (Vitrification)	Slow cooling	Reimplantation	Overt night Transport	Central CryobankGnRH agonist hCG	Improved	Fertility preservation	35 to 40%
Fresh embryos	Direct Frozen Embryo Transfer	Ethylene Glycerol Freeze Media	Embryo preservation Vitrification	Vitrification vs slow programmable freezing SPF	SPF	IVF	Sub zero temperature	Lower	Ovarian Stimulation Syndrome (OVSS)	27to 30%
Frequent in frozen embryo transfer (FRET) cycles	Cryopreserve embryo	Cryostorage	Vitrification	SPF	IVF	Quickly	Embryo preserve	Improved	Implantation potential	50 to 70%
Endometrium preparation	Cryopreserve embryo	Cryostorage	Vitrification	SPF	IVF Endometrial exposure	Slowly	Blastocysts with exogenous estradiol and progesteron	Excellent	Blastocyst implantation	98%
Embryo	Standard Freezing Method	Cryoprotectant	Tank of liquid nitrogen	Slowly frozen down to -196°C	Glass like solidification	According to HFE ACT 1990, 2008	Embryo preservation	Good	Fertility	50 to 75%
Blastocysts	Blastocyst Transfer	Premeating (egpropanediol (Non-permeating or extracellular e.g., sucrose)	SF	IVF	Slow Freezing	IVF egg retrievals	Excellent	Blastocyst transfer	Excellent	99%
Fresh pre-embryos	Frozen cycle Transfer	Sucrose	Vitrification	FT	After biopsy	More quickly	Cryopreserved embryo	Excellent	Fresh embryo	60 to 70%
Hematopoietic stem cells	Standard Freezing method	DMSO 10%	Cryopreserved after collection	Membrane stabilizer and bio oxidants	Slowly (CFM)	-80°C	Good	Human umbilical cord blood	Mechanical freezer	30 to 50%
Umbilical cord blood (UCB)	An automated microprocessor controlled rate freezer	DMSO 10%	1.Cryotubes 2.Aluminium cassette in the chamber of the cell freezer 10%	1°C to -120°C	Liquid Nitrogen Freezer	Liquid phase of a liquid nitrogen	-60°C to -120°C	Good	Transplantation	80 to 90%
Human Spermatozoa	Conventional freezing techniques (manual and automated)	Human albumin 10%	Direct Swimp Or Density gradient centrifugation	IVF	Slow	GRS	ICSI cycle with fresh cryopreserved	Good	Liquid nitrogen vs computerized program freezer	40 to60%
<i>In vitro</i> fertilization (IVF)	Pre-IVF semen analysis	Embryos and thawed	Selection gamete	Liquid nitrogen level	Slow	GRS	Frozen embryos	-196°C	ART	25 to 50%

Contd...

Table 1: Contd...

OR	DM	CPT	CPV	CT	OR	ST	FT	SV	SF	SR + RM
Intracytoplasmic sperm injection (ICSI)	IVF/ICSI procedure	Frozen and thawed epididymal spermatozoa	Injected Oocyte	Normal	2(PN)	motile	Freshly retired spermatozoa	Good	Pregnancy spermatozoa	30 to 60%
Semen	Sperm Banking	Glycerol 10%	Cryopreserved sperm	Thawing at 40°C	ATP content and DNA	Well controlled cooling regime	Slow programming freezing	Vitrification	Potentially improved	60to85%
Gamete	Standard method	Glycerol solution	4-cell stage embryo	37°C in a 5% air incubator	Trans cervical	Transfer non frozen	-196°C	Improved	Vitrification	70 to 80%
Follicle	Harvest culture	Mature Oocytes + cryostorage	Frozen and Thawed Ovarian tissue	Most abundant stage	Triple stage process	Isolation of granulosa Oocyte complexes	Vitrification (SF)	Slowly developing	Primordial Follicles	10 to 15%
Autologous Transplantation Human lymphocytes	DMS	Ovaredonized fresh ovary	-55°C	0.5°C/min	Ice nucleation at -7°C	Plugged 7 to 15 days	Liquid nitrogen	Improved	Transplantation	60 to 70%
GnRH antagonists	Simple and quick	Cryostorage	Frozen storage	GVH and NLT reaction	Allogeneic lymphocytes (cytotoxic)	Survived Freezing	Frozen and stored	Slowly	Secret complement dependents leucocytes antibodies	10 to 30%
ZPN oocytes	Simple and Rapid	Diluted cryoprotectants (Glycerol)	Egg yolk PH, buffers (TES and TRIS)	Transferred straws	Lebelling and recording	Frozen	-37°C	Up to 24 hours	GHT	70 to 80%
Hepatocytes	Rapid CFC	Glycerol 5 to 10%	Oocyte bank Cryopreservation	Slow Frozen	Control rate	Slow Freezing	The egg must be dehydrated before freezing	2-4 weeks	Good	40 to 60%
Fluid from the intravascular compartment Bone marrows	Hepatocytes Cryopreservation protocol	Cryopreservation media	Hepatocyte	Liver cell freezing solution	Less than 10000000 cell	Law density	37°C	48 hours preculture	Good	25 to 50%
Mature blood cells	Transcellular compartment	Mg and sulphations	Osmotic equilibrium	Plasma membrane	Intestinal fluid	Fresh embryo	24 to 36 hours	ICG	Good	20 to 25%
	Liquid culture	Cryo storage	Harvest	Colony Forming cells	Auto lab T	Myeloid	Prolonged	BMT	Good	40 to 50%
	Simple method	Cryostorage	Extracellular space	MBS	Nucleated cells 1%	BMC product	Mega karyocytic progenitor cells	CD 15 + myeloid cells	Good	30 to 50%

N.B. Si: Serial number, OR: Organism/cells or tissue, CPT: Cryoprotectants, CPV: Cryopreserve, CT: Cooling time, OR: Oocyte rate, ST: Storage time, FT: Freezing tolerance, SV: Survivability, SF: Significance, RM: Remarks, GIFT: Gamete intra fallopian transfer

DISCUSSION

Ovarian tissue and transplantation

As per existing literature from 2000 to 2016 we have provided the accountability of cryopreservation.^[10] We concluded that advances in reproductive technology have made fertility preservation techniques are all possibility for patients whose gonad function is threatened by premature menopause by treatments such as radiotherapy, chemotherapy, or surgical castration^[10] Female cancer patients can access “banking” of gametes before therapy. In addition to transplant patients fresh and frozen ovarian tissues are required for both fertile and infertile women.

Researchers now developed the utility of the tissue banked for the restoration of endocrine and fertility function. In addition to methods such as follicle culture and isolated follicles are required for transplantation in developmental stages. More than 30 transplantations of cryopreserved tissue have been reported and six babies have been born, worldwide, following this procedure. Despite these encouraging results, it is essential to optimize the procedure by improving the follicular survival for confirming safety and clinical use.^[11]

Implantation potential and clinical impact (IPCAI)

Potential abilities of human embryos to survive the freezing and thawing process and reflected in their implantation. Cryopreservation affect adversely in the capacity of human embryos to implant. In multiple pregnancies are FRET cycles having no conclusive evidence on the stages of development. Fresh cycle evidence suggested that there are no adverse consequences in the babies born after embryo cryopreservation.^[12] Cryopreserved and thawed blastocysts demonstrated a similar pattern of implantation.^[13]

Hematopoietic stem cells (HSC)

Stem cell transplantation represents a critical approach for the treatment of many malignant and nonmalignant diseases. The function of these approaches is the ability to cryopreserve marrow cells for future use. This technique is routinely employed in all autologous settings and is critical for cord blood transplantation.^[14] HSC can be stored for prolonged periods at cryogenic temperatures. New techniques currently used are derived from the initial report in 1949 of cryopreservation of bovine sperm in glycerol. In addition to glycerol penetrating cryoprotectant protected the cells, from the injury associated through ice formation. Current cryopreservation techniques with several minor variations suspend cells in an aqueous solution of ions, salts, protein, and other

cryoprotectants. Cells are frozen at slow rates and stored generally below -120°C in mechanical freezers or nitrogen refrigerators. These techniques are successful in maintaining HSC viability that is evident from the engraftment of these cells in patients treated with marrow-lethal-conditioning regimens. Basically, the composition of the cryoprotectant solution, cell concentration during freezing, cryoprotectant toxicity, and storage temperatures have not been adequately studied, primarily because lack of appropriate assays for HSC cryosurvival. HSC cryobiology will become an increasingly important subject as new HSC collection and processing techniques are developed. Improved cryosurvival of HSC using modified cryoprotectant solutions may improve engraftment kinetics and decrease cost. It decreases the morbidity of autologous transplantation patients.^[15] In cryopreservation, processis of importance for all types of stem cell collection. Particularly, critical for UCB. The actual transplant is harvested at the time of birth and used in the determination of recipient. UCB is usually stored by either public or private cord blood banks (CBBs). Public CBBs are usually nonprofit organizations that offers the donor unit to matching recipients registered in national or international registries.^[16] CBBs were stored at donor specimen and unknown recipient for later application. There are 170,000 frozen units in 37 cord blood registries were seen in 21 countries. A total of 3000 units been transplanted till date.^[17]

Human spermatozoa

Freeze human spermatozoa and the possibility of pregnancy followed by intrauterine insemination existed for more than 45 years.^[18] Now there have been improvements in the methods of freezing and thawing human spermatozoa. Cryoprotective used was glycerol. Minor limitations were observed in the motility recovery. Ultra-structural damage sensitive criteria and objective assessment of morbidity/motility required for their energy status. Additionally damages in the plasma membrane or subcellular elements (like the chromatin stability and chromosomal damage) are needed. Sperm cryopreservation needs different kinds of biochemical environment and physical conditions. Biochemical changes are assessed following different combinations to avoid the increase in osmotic pressure. Hence, we need additional studies to arise from the extensive use of frozen spermatozoa during ARTs, all together with the development to assisted fertilization.^[19] New methods of human spermatozoa preservation developed. There is no doubt that the use of frozen-thawed semen has revolutionized domestic animal breeding programs. It allows rapid genetic improvement which facilitated the distribution of germ plasma worldwide.^[20] Cryopreservation of male gametes provides increased treatment options in the

case of spontaneous or iatrogenic infertility at various developmental stages and ages.^[21]

Safety and effectiveness of tissues in cryopreservation

Human Fertilization and Embryology Authority focused on the safe cryopreservation of gametes and embryos. Human fertilization and embryology authority (HFAEA) focused on the safe cryopreservation of gametes and embryos. There is a need for development of fertility clinics in the UK and India to preserve the spermatozoa. We ensured that containers used for cryopreservation should withstand low temperatures. We can use secondary containers and store in nitrogen vapor as an alternative. A number of issues related to vapor storage, needs a careful consideration. In addition to safety, cost effectiveness of various storage techniques for maintaining gamete and embryo viability should not be ignored.^[22]

Human lymphocytes

Human lymphocytes are cryopreserved through a variety of *in vitro* immunologic studies to determine the applicability of using a programmable freezing system, comparing glycerol versus DMSO at varying concentrations on post thaw viability, E-resetting, and immunoglobulin fluorescence including pre-and post-freeze T and B lymphocyte percentages were determined according to generated data on post-thaw. T and B percentages revealed 10% DMSO and liquid nitrogen control at 1°C/min as the best condition for lymphocyte preservation.^[23]

Hepatocytes

Hepatocytes are routinely used in human biomonitoring to assess the potential toxic and cryoprotective effects of diet on both DNA damage and tissue repairing.^[24] Hepatocytes have been investigated for many years as a method of long-term storage. Unfortunately, an agreed acceptable protocol has not emerged partly due to the susceptibility of hepatocytes to the freeze-thaw process (which is essential nowadays).^[25] Cryopreserved human hepatocytes are extensively used now a days for post-thaw viability and determine by trypan blue exclusion, ranged from 55% to 85%. Hepatocytes are cryopreserved from 17 donors post-thaw viability and found to be stable up to the longest period of 120 days.^[26]

Gonadotropin releasing hormone antagonists

Presently pregnancy associated with blockage of oocytes and GnRHa is a major concern. These oocytes can be used at a later stage. The quality of transferred embryos and the pregnancy rates in the freeze-thaw cycles used carefully.^[27] Cryopreserved ZPN oocytes can be replaced after thawing even in the cleavage stage condition.^[28]

Embryo freezing for preventing ovarian hyperstimulation syndrome

Ovarian hyper stimulation syndrome (OHSS) is an iatrogenic potentially life-threatening condition resulting from an excessive ovarian stimulation. Its reported incidence varies from 1% to 10% of IVF cycles. That release of vasoactive substances secreted by the ovaries under human chorionic gonadotropin stimulation. Which is plays a key role in triggering this syndrome. Cryopreservation condition are varies in massive shift of fluid from the intravascular compartment. The third space also resulting profound intravascular depletion.^[29] Randomized controlled trials (RCT) in human intravenous albumin or cryopreservation of all embryos were used as a therapeutic approach. Women participants were of reproductive age, who were down regulated by GnRH and undergoing superovulation in IVF/ICSI cycles.^[30] The interventions compared with cryopreservation (embryo freezing) versus intravenous human albumin administration. Elective cryopreservation of all embryos versus fresh embryo transfer necessary for primary outcomes. The incidence of moderate to severe OHSS versus nil/mild OHSS, clinical pregnancies/woman varies from countries to countries.^[31] In addition to Cochrane menstrual disorders and subfertility group guidelines also clarifying the same.^[32] Cryopreservation (embryo freezing) was compared with intravenous human albumin administration through elective cryopreservation having the potential application.^[33]

Hematopoietic stem cell processing (HSCP)

Bone marrow or peripheral blood may be harvested to provide HSC for autologous transplantation and compromise heterogeneous cell populations. HSC are necessary for successful engraftment and constitute. There is a very small fraction of the cells harvested. After collection, the harvested cells usually undergo several new processes to reduce the product volume, remove cells (such as MBCs or tumor cells). In cryopreserving the cells for later reinfusion, granulocytes and red blood cells, survive cryopreservation poorly using freezing techniques designed for HSC. Therefore, bone marrows being cryopreserved must be dependent on MBCs. MBCs are impeding the variety of tumor cells. Purging techniques processed through different study design minimize the loss of HSC. While achieving an appropriate HSC product for the individual patient number of apheresis devices and cell washers. Simply the enrichment to HSC in the harvested cell products were in contrast to tumor cell purging techniques, which were not standardized between the various transplant centers.^[34] Liquid nitrogen freezers are not sterile, and both the liquid and vapors phases are potential sources of microbial contamination of

hematopoietic progenitor cell components. The low-level contamination by environmental organisms was very common. The occurrence of heavy contamination by potential pathogens such as aspergillus species suggest that monitoring of liquid nitrogen sterility indicating the safe strategies to assess and prevent microbial transmission from liquid nitrogen to HPLC components need further development.^[35-37] The clinical evidence of HSCs with UCB/PCB grafts indicated that PCB is one useful resource of HSCs for routine bone marrow reconstitution. The large registry study confirms the potential benefit of using UCBHSCs for allogenic transplants.^[38]

Ovarian tissue and oocyte

Ovarian tissue cryopreservation and oocyte cryopreservation hold promise for future female fertility preservation. Treatment protocols for immature ovarian grafting for puberty and fertility be developed. The data of researchers suggested that follicle depletion leads to premature ovarian failure. It provides valuable information to the study of ovarian transplantation suggesting that these procedures do not produce normal epigenetic marks. These results are highly relevant to the reimplantation question of immature cortex among women.^[39]

Ovarian cryopreservation

Whole ovary tissue was equilibrated at 4°C for 30 min in cryogenic vials containing Brahma 1 solution with 10% bovine calf serum and 1.5 M DMSO. These vials were transferred to a programmable freezer (planner products, cryobirysten) and cooled at 2°C/min for seeding. Followed by freezing 0.3°C/min to -40°C and subsequently at 10°C/min to -140°C. Vials were stored in liquid nitrogen, for approximately 2–4 weeks only. Before grafting, tissues were rapidly warmed in air at room temperature for 30 s. Then immersed in water at 30–35°C for 5 min. The ovaries were removed from the cryovials and placed successively in 4 solutions containing decreasing DMSO concentrations. After washing, ovaries were placed in Leibovitz-L15 medium, at room temperature, and grafted within 15 min of thawing. The development and potential impact of ovarian cryopreservation upon assisted fertility and in the restoration of ovarian function of cancer and the menopausal treatment.^[40]

Future of cryopreservation

Advances in the cryopreservation of eggs harvested from hormonal treatment cycles may be used to develop egg banks in the same way as sperm banks are used now. Unfertilized eggs developed into normal healthy children, and the number of successful births can be enhanced greatly. This is a preferred technology in assisted fertility treatment. The use of egg banks

allow mothers to delay child bearing until middle age. Recent advances in ovarian cryopreservation and transplantation will make it theoretically possible to restore fertility after menopause. The applications in mammalian cells are virtually limitless and useful tool in a variety of fields such as pediatrics, pediatric surgery, pathology, nuclear medicine, medical oncology, transplant biology, stem cell facilities, and nanotechnology.

Suggestion and further investigation for future generation

Long-term follow-up studies required special attention to measure the impact of ART on patients, parents and relatives. Oocyte manufacturing alleviated the burden of age-related infertility problem.

CONCLUSION

The cryopreservation technology helps female infertility, organ transplantation, and stem cell development through bone marrow transplantation (BMT).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Faupel RP, Seitz HJ, Tarnowski W, Thiemann V, Weiss C. The problem of tissue sampling from experimental animals with respect to freezing technique, anoxia, stress and narcosis. A new method for sampling rat liver tissue and the physiological values of glycolytic intermediates and related compounds. *Arch Biochem Biophys* 1972;148:509-22.
2. Barik M, Bajpai M, Malhotra A, Samantaray JC, Dwivedi SN. Does cryopreservation technology help to forensic medicine and tissue engineering? *J Med Toxicol* 2014;2:31-5.
3. Barik M. Cryopreservation Technology is an Effective Tool for Clinical Application and Research. *BMJ International Conference Bulletin, Clinical Epidemiology Unit*. Vol. 1. New Delhi: AIIMS; 2012. p. 81.
4. Berz D, McCormack EM, Winer ES, Colvin GA, Quesenberry PJ. Cryopreservation of hematopoietic stem cells. *Am J Hematol* 2007;82:463-72.
5. Wennerholm UB, Söderström-Anttila V, Bergh C, Aittomäki K, Hazekamp J, Nygren KG, *et al.* Children born after cryopreservation of embryos or oocytes: A systematic review of outcome data. *Hum Reprod* 2009;24:2158-72.
6. Bernard A, Fuller BJ. Cryopreservation of human oocytes: A review of current problems and perspectives. *Hum Reprod Update* 1996;2:193-207.
7. Gook DA, Edgar DH. Human oocyte cryopreservation. *Hum Reprod Update* 2007;13:591-605.
8. American Cancer Society. *Cancer Facts and Figures*. Atlanta: American Cancer Society; 2001. Available from: <http://www.cancer.org/acs/groups/content/@epidemiologysurveillance/documents/document/acspc-036845.pdf>. [Last retrieved on 2007 Apr 24].
9. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. *Reprod Biomed Online* 2009;18:769-76.
10. Gook DA, Edgar DH. Cryopreservation of the human female gamete: Current and future issues. *Hum Reprod* 1999;14:2938-40.
11. Smits J, Dolmans MM, Donnez J, Fortune JE, Hovatta O, Jewgenow K,

- et al.* Current achievements and future research directions in ovarian tissue culture, *in vitro* follicle development and transplantation: Implications for fertility preservation. *Hum Reprod Update* 2010;16:395-414.
12. Demeestere I, Simon P, Emiliani S, Delbaere A, Englert Y. Orthotopic and heterotopic ovarian tissue transplantation. *Hum Reprod Update* 2009;15:649-65.
 13. Kolibianakis EM, Zikopoulos K, Devroey P. Implantation potential and clinical impact of cryopreservation – A review. *Placenta* 2003;24 SupplB: S27-33.
 14. Veeck LL, Bodine R, Clarke RN, Berrios R, Libraro J, Moschini RM, *et al.* High pregnancy rates can be achieved after freezing and thawing human blastocysts. *Fertil Steril* 2004;82:1418-27.
 15. Rowley SD. Hematopoietic stem cell processing and cryopreservation. *J Clin Apher* 1992;7:132-4.
 16. Valeri CR, Pivacek LE. Effects of the temperature, the duration of frozen storage, and the freezing container on *in vitro* measurements in human peripheral blood mononuclear cells. *Transfusion* 1996;36:303-8.
 17. Sanz MA. Cord-blood transplantation in patients with leukemia – A real alternative for adults. *N Engl J Med* 2004;351:2328-30.
 18. D'Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: Acochrane review. *Hum Reprod* 2002;17:2787-94.
 19. Watson PF. Artificial insemination and the preservation of semen. In: Lamming G, editor. *Marshall's Physiology of Reproduction*. Edinburgh, London: Churchill Livingstone; 1990. p. 747-869.
 20. Hallak J, Mahran A, Chae J, Agarwal A. The effects of cryopreservation on semen from men with sarcoma or carcinoma. *J Assist Reprod Genet* 2000;17:218-21.
 21. Holt WV. Fundamental aspects of sperm cryobiology: The importance of species and individual differences. *Theriogenology* 2000;53:47-58.
 22. Tomlinson M, Sakkas D. Is a review of standard procedures for cryopreservation needed? safe and effective cryopreservation-should sperm banks and fertility centres move toward storage in nitrogen vapour? *Hum Reprod* 2000;15:2460-3.
 23. Hammerstedt RH, Graham JK, Nolan JP. Cryopreservation of mammalian sperm: What we ask them to survive. *J Androl* 1990;11:73-88.
 24. Duthie SJ, Pirie L, Jenkinson AM, Narayanan S. Cryopreserved versus freshly isolated lymphocytes in human biomonitoring: Endogenous and induced DNA damage, antioxidant status and repair capability. *Mutagenesis* 2002;17:211-4.
 25. Lloyd TD, Orr S, Skett P, Berry DP, Dennison AR. Cryopreservation of hepatocytes: A review of current methods for banking. *Cell Tissue Bank* 2003;4:3-15.
 26. Li AP, Chuang LV, Brent LA, Pham C, Fackett A, Charles E, *et al.* Cryopreserved human hepatocytes: Characterization of drug metabolizing activities and applications interactions in higher through put screening assays for hepato-toxicity, metabolic stability and drug interaction potential. *Chem Biol Interact* 1999;121:17-35.
 27. Nikolettos N, Asimakopoulos B, Simopoulou M, Al-Hasani S, Diedrich K. Gonadotropin releasing hormone antagonists and cryopreservation outcome: A review. *Arch Gynecol Obstet* 2004;270:69-73.
 28. Seelig AS, Al-Hasani S, Katalinic A, Schöpfer B, Sturm R, Diedrich K, *et al.* Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. *Fertil Steril* 2002;77:472-5.
 29. D'Angelo A. Embryo Freezing for Preventing Ovarian Hyperstimulation Syndrome. *Med Scap Latest News CME Conferences Resource Centers Patient Ed. Cochrane Rev Abstract*; 2006.
 30. Hughes E, Brown J, Collins JJ, Vanderkerchove P. Clomiphene citrate for unexplained subfertility in women. *Cochrane Database Syst Rev* 2010;1CD000057.
 31. D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. *Cochrane Database Syst Rev* 2007;2CD002806.
 32. Jacobson TZ, Duffy JM, Barlow D, Farquhar C, Koninckx PR, Olive D. Laparoscopic surgery for subfertility associated with endometriosis. *Cochrane Database Syst Rev* 2010;1:CD001398.
 33. Clarke GN. Sperm cryopreservation: Is there a significant risk of cross-contamination? *Hum Reprod* 1999;14:2941-3.
 34. Fountain D, Ralston M, Higgins N, Gorlin JB, Uhl L, Wheeler C, *et al.* Liquid nitrogen freezers: A potential source of microbial contamination of hematopoietic stem cell components. *Transfusion* 1997;37:585-91.
 35. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. *Exp Hematol* 2000;28:1197-205.
 36. Navarro-Costa P, Correia SC, Gouveia-Oliveira A, Negreiro F, Jorge S, Cidadão AJ, *et al.* Effects of mouse ovarian tissue cryopreservation on granulosa cell-oocyte interaction. *Hum Reprod* 2005;20:1607-14.
 37. Gosden RG, Baird DT, Wade JC, Webb R. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at -196 degrees C. *Hum Reprod* 1994;9:597-603.
 38. Fabbri R, Porcu E, Marsella T, Primavera MR, Seracchioli R, Ciotti PM, *et al.* Oocyte cryopreservation. *Hum Reprod* 1998;13 Suppl 4:98-108.
 39. Sonigo C, Simon C, Boubaya M, Benoit A, Sifer C, Sermondade N, Grynberg M. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after *in vitro* maturation? *Hum Reprod* 2016;31:1493-500.
 40. Lopes CA, Alves AM, Jew genow K, Bao SN, deFigueiredo JR. Cryopreservation of canine ovarian cortex using DMSO or 1, 3-propanediol. *Theriogenology* 2016;16:30035-6.